Back to results
US 2003/0199520 A1Published application
Sulfonamide hydroxamates
AssigneeSyntex (U.S.A.) Inc.
InventorsRoland Joseph Billledeau, Chris Allen Broka, Jeffrey Allen Campbell, Jian Jeffrey Chen, Sharon Marie Dankwardt, Nancy Delaet, Leslie Ann Robinson, Keith Adrian Murray Walker
Life of this patent
Estimating the term…
Abstract
This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
Claims52
A compound selected from the compounds of Formula (I):
- 36
- wherein:
- Z is —OH, —NHOH, or OR12 wherein R12 is alkyl;
- R1 is alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclylalkyl, cycloalkylalkyl, -(alkylene)-C(O)—X where X is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, amino, monosubstituted amino, disubstituted amino, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, hydroxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, heteroalkyloxy, aralkyloxy, or heteroaralkyloxy), or —C(═NR′)NHSO2R″ (where R′ is hydrogen or alkyl, and R″ is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or heterocyclylalkyl);
- R is —CH(R2)Ar1 or —CH(R2)CH═CHAr1 where R2 is hydrogen or alkyl;
- and Ar1 is aryl or heteroaryl;
- Ar2 is either:
- (i) a phenyl ring of formula (a):
- 37
- wherein:
- R3 and R7 are, independently of each other, hydrogen, alkyl, alkylthio, or halo;
- R4 and R6 are, independently of each other, hydrogen, alkyl, or halo;
- R5 is alkyl, haloalkyl, heterocyclyl, alkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, cycloalkylthio, cycloalkylalkylthio, alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyloxy, cycloalkoxy, cycloalkylalkoxy, alkyloxycarbonyl, hydroxy, halo, cyano, carboxy, nitro, amino, monoalkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, heteroarylsulfonyl, heteroaralkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfonyl, or —Y-(alkylene)-C(O)—Z [where Y is a bond, —NRa—, —O—, or —S(O)n— (where n is 0 to 2), Ra is hydrogen or alkyl, and Z is alkoxy, hydroxy, amino, monosubstituted amino, or disubstituted amino];
- or
- R5 together with R4 forms —O—(CR8R9)n— where n is 2 or 3 and each R8 and R9 are, independently of each other, hydrogen or alkyl;
- or
- the carbon atoms to which R5 and R4 are attached are fused to the C2-C3 carbons of a benzofuran ring;
- provided that at least two of R3, R4, R6, and R7 are not hydrogen at the same time;
- or
- (ii) a naphthyl ring of formula (b):
- 38
- wherein:
- R10 is hydrogen, alkyl, alkoxy, or halo;
- and
- R11 is hydrogen, alkyl, haloalkyl, alkylthio, alkoxy, alkyloxycarbonyl, aryloxy, hydroxy, halo, cyano, carboxy, nitro, amino, monoalkylamino, dialkylamino or alkylsulfonyl provided that both R10 and R11 are not hydrogen at the same time;
- and
- their pharmaceutically acceptable salts, prodrugs, individual isomers, and mixtures of isomers.
24 more elements
A method of treatment of a disease treatable by administration of a therapeutically effective amount of a pro-collagen C-proteinase inhibitor of Formula (Ib) wherein:
- 39
- wherein:
- R1 is alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclylalkyl, cycloalkylalkyl, -(alkylene)-C(O)—X (where X is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, amino, monosubstituted amino, disubstituted amino, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, hydroxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, heteroalkyloxy, aralkyloxy, or heteroaralkyloxy), or —C(═NR′)NHSO2R″ (where R′ is hydrogen or alkyl, and R″ is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or heterocyclylalkyl);
- R is —CH(R2)Ar1 or —CH(R2)CH═CHAr1 where R2 is hydrogen or alkyl;
- and Ar1 is aryl or heteroaryl;
- Ar2 is either:
- (i) a phenyl ring of formula (a):
- 40
- wherein:
- R3 and R7 are, independently of each other, hydrogen, alkyl, alkylthio, or halo;
- R4 and R6 are, independently of each other, hydrogen, alkyl, or halo;
- R5 is alkyl, haloalkyl, heterocyclyl, alkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, cycloalkylthio, cycloalkylalkylthio, alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyloxy, cycloalkoxy, cycloalkylalkoxy, alkyloxycarbonyl, hydroxy, halo, cyano, carboxy, nitro, amino, monoalkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, heteroarylsulfonyl, heteroaralkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfonyl, or —Y-(alkylene)-C(O)—Z [where Y is a bond, —NRa—, —O—, or —S(O)n— (where n is 0 to 2), Ra is hydrogen or alkyl, and Z is alkoxy, hydroxy, amino, monosubstituted amino, or disubstituted amino];
- or
- R5 together with R4 forms —O—(CR8R9)n— where n is 2 or 3 and each R8 and R9 are, independently of each other, hydrogen or alkyl;
- or
- the carbon atoms to which R5 and R4 are attached are fused to the C2-C3 carbons of a benzofuran ring;
- or
- (ii) a naphthyl ring of formula (b):
- 41
- wherein:
- R10 is hydrogen, alkyl, alkoxy, or halo;
- and
- R11 is hydrogen, alkyl, haloalkyl, alkylthio, alkoxy, alkyloxycarbonyl, aryloxy, hydroxy, halo, cyano, carboxy, nitro, amino, monoalkylamino, dialkylamino or alkylsulfonyl;
- and
- their pharmaceutically acceptable salts, prodrugs, individual isomers, and mixtures of isomers.
22 more elements
Dependencies are inferred from the claim text.